Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents

SA Johnson, T Fang, F De Marchi, D Neel… - Drugs, 2022 - Springer
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …

Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents

SA Johnson, T Fang, F De Marchi, D Neel… - Drugs, 2022 - research.uniupo.it
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …

Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.

SA Johnson, T Fang, F De Marchi, D Neel… - Drugs, 2022 - europepmc.org
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3-5 …

Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents

SA Johnson, T Fang, F De Marchi, D Neel… - Drugs - pubmed.ncbi.nlm.nih.gov
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3-5 …

[引用][C] Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents

SA Johnson, T Fang, F De Marchi, D Neel… - Drugs, 2022 - biblio.ugent.be
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming
Agents Universiteit Gent Add publications and datasets Lists Sign in Academic Bibliography …

Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents

SA Johnson, T Fang, F De Marchi, D Neel… - Drugs, 2022 - research.uniupo.it
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …